Viking Therapeutics (1VT) AI Stock Analysis

76 Followers

Viking Therapeutics

(XETRA:1VT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Clinical Pipeline ProgressAdvancing both injectable and oral VK2735 programs into late-stage trials strengthens Viking’s development platform and expands potential product formats. Fully enrolled studies and a new registration program create multiple upcoming clinical milestones that could support future commercialization if results and regulatory reviews are favorable.

Negative Factors

No Commercial Revenue and Widening LossesViking has not yet established a commercial revenue stream to offset research and operating costs, leaving its financial outlook dependent on clinical progress and future product approval. Rapidly widening losses increase the amount of capital required before the business can potentially become self-funding.

Viking Therapeutics (1VT) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.33B
Dividend Yield: ―
Average Volume (3M): 815
Price to Earnings (P/E): -4.8
Beta (1Y): 0.87
Revenue Growth: ―
EPS Growth: -145.97%
Country: Germany
Employees: 65
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Viking Therapeutics Business Overview & Revenue Model

Company Description

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered,...

Viking Therapeutics Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:7.87%|Next Earnings Date:Feb 09, 2027

Earnings Call SentimentPositive

The call was strongly positive on clinical and operational progress. Viking reported fully enrolled and on-track subcutaneous Phase III studies, initiation of the oral Phase III program, encouraging efficacy and tolerability results from VK2735 maintenance studies, advancement of VK3019, and a substantially strengthened cash position. The main negative factors were sharply higher operating expenses, a substantially wider net loss, ongoing cash usage of around $100 million per quarter, and uncertainty around future maintenance-study and regulatory outcomes. Highlights significantly outweighed lowlights.

Positive Updates

VANQUISH Phase III Program Remains on Track

Both Phase III VANQUISH studies of subcutaneous VK2735—VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes—are fully enrolled and continued to advance according to plan. The studies evaluate weekly doses of 7.5 mg, 12.5 mg and 17.5 mg over 78 weeks, with the first patients expected to enter extension periods in early 2027.

Negative Updates

Quarterly Research and Development Expenses Increased

Third-quarter research and development expenses rose to $166.8 million from $90.0 million in the same period of 2025, an increase of approximately 85%. The increase was primarily attributed to higher clinical-study expenses, manufacturing, stock-based compensation, salaries and benefits, and third-party consultants, partially offset by lower preclinical-study expenses.

Company Guidance

Viking expects the first patients to enter the VANQUISH extension period in early 2027, with the subcutaneous VANQUISH studies assessing once-weekly dosing for 78 weeks; it expects to complete the VK3019 single ascending dose study later this quarter, or by year-end, and plans to initiate a multiple ascending dose study in the first quarter of 2027. The SUNRISE Phase III studies will evaluate oral VK2735 dosed once daily for 68 weeks at 27.5 milligrams, 35 milligrams, 55 milligrams or placebo, with 4-week titration blocks, while Part 2 of the maintenance study will evaluate oral doses ranging from around 17 to 55 with 5 arms, plus 6 subcu arms, 3 every other week and 3 monthly, with results expected in 2027. The company expects a cash usage of average of around $100 million per quarter, with some quarters higher and some lower, SG&A fairly flat in the near term and a pickup later more toward commercialization, which is 2.5 years out from potential launch.

Viking Therapeutics Risk Analysis

Viking Therapeutics disclosed 77 risk factors in its most recent earnings report. Viking Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Risk Factor SummaryQ2, 2026

Viking Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1VT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NAMS	52Neutral	$2.34B	-9.13	-38.33%	―	-88.87%	-35.06%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GPCR	51Neutral	$1.46B	-6.72	-16.91%	―	―	1.47%
MLYS	50Neutral	$1.37B	-3.77	-57.97%	―	―	-19.00%
PBLS	42Neutral	$3.37B	-0.79	-15.14%	―	―	―

* Healthcare Sector Average

Performance Comparison

DE:1VT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1VT	Viking Therapeutics	24.00	-6.38	-21.00%
NAMS	Newamsterdam Pharma Company N.V.	19.90	-18.22	-47.80%
MLYS	Mineralys Therapeutics, Inc.	15.99	-23.66	-59.67%
GPCR	Structure Therapeutics, Inc. Sponsored ADR	20.35	-11.86	-36.82%
KLRA	Kailera Therapeutics, Inc.	12.58	-13.42	-51.62%
PBLS	Parabilis Medicines, Inc.	29.25	-2.35	-7.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Viking Therapeutics AI Stock Analysis